8-K
filed October 3, 2022, 7:59 PM ET
ticker IPSC
CIK 0001850119
leadership
confidence high
sentiment neutral
materiality 0.50
Century Therapeutics adds Quimi and Walbert to board after Casdin resigns
Century Therapeutics, Inc.
- Eli Casdin resigned as Class I director effective Oct 1, 2022, not due to any disagreement with the Company.
- Board expanded to 8 seats; appointed Daphne Quimi (CFO of Amicus Therapeutics) as Class I director.
- Appointed Timothy P. Walbert (CEO of Horizon Therapeutics) as Class II director.
- Quimi joins Audit and Nominating/Governance committees; Walbert joins Compensation Committee.
- Each received a non-qualified option for 39,744 shares at $9.89, vesting over 36 months.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Eli Casdin resigned as Director at Century Therapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Eli Casdin tendered his resignation as a member of the board of directors (the “ Board ”) of Century Therapeutics, Inc.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Timothy P. Walbert was appointed as Director at Century Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
and (ii) Mr. Timothy P. Walbert to serve as a Class II director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daphne Quimi was appointed as Director at Century Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board appointed (i) Ms. Daphne Quimi to serve as a Class I director of the Company
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.